Who are Matching placebo to pioglitazone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): pioglitazone + simvastatin, metformin\pioglitazone\exenatide, oral hypoglycemic agents, IMP Pioglitozone, Rosiglitazone and Pegasys/Ribavirin, CSII, Metformin, Pioglitazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/matching-placebo-to-pioglitazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Matching placebo to pioglitazone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Matching placebo to pioglitazone (Matching placebo to pioglitazone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione. Area: Diabetes.

phase 3 Thiazolidinedione PPAR-γ (Peroxisome proliferator-activated receptor gamma) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Matching placebo to pioglitazone (Matching placebo to pioglitazone) — Merck Sharp & Dohme LLC. This is a placebo control arm matching pioglitazone, a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Matching placebo to pioglitazone TARGET	Matching placebo to pioglitazone	Merck Sharp & Dohme LLC	phase 3	Thiazolidinedione	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
pioglitazone + simvastatin	pioglitazone + simvastatin	University of Leipzig	marketed	Thiazolidinedione + HMG-CoA reductase inhibitor combination	PPAR-γ (pioglitazone); HMG-CoA reductase (simvastatin)
metformin\pioglitazone\exenatide	metformin\pioglitazone\exenatide	The University of Texas Health Science Center at San Antonio	marketed	Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist)	Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide)
oral hypoglycemic agents	oral hypoglycemic agents	Queen Elizabeth II Health Sciences Centre	marketed	Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)
IMP Pioglitozone	IMP Pioglitozone	University of Nottingham	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)
CSII, Metformin, Pioglitazone	CSII, Metformin, Pioglitazone	Sun Yat-sen University	marketed	Insulin + biguanide + thiazolidinedione combination	Insulin receptor (CSII); AMPK/mitochondrial function (metformin); PPAR-γ (pioglitazone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione class)

Merck Sharp & Dohme LLC · 3 drugs in this class
GlaxoSmithKline · 1 drug in this class
Medical University of South Carolina · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Matching placebo to pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/matching-placebo-to-pioglitazone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab